Poly (ADP-ribose) polymerase (PARP) inhibitor regimens ...

Network meta-analysis found no significant differences in efficacy and toxicity among PARPi regimens for BRCA-mutated ovarian cancer. ASCO value framework showed similar clinical benefits and toxicity, but higher costs for combined therapies. Upfront PARPi regimens are less toxic than relapse treatments. Cost-effectiveness should guide regimen choice.